154 related articles for article (PubMed ID: 31021852)
61. Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study.
Hosseinipour M; Nelson JAE; Trapence C; Rutstein SE; Kasende F; Kayoyo V; Kaunda-Khangamwa B; Compliment K; Stanley C; Cataldo F; van Lettow M; Rosenberg NE; Tweya H; Gugsa S; Sampathkumar V; Schouten E; Eliya M; Chimbwandira F; Chiwaula L; Kapito-Tembo A; Phiri S;
J Acquir Immune Defic Syndr; 2017 Jun; 75 Suppl 2(Suppl 2):S149-S155. PubMed ID: 28498184
[TBL] [Abstract][Full Text] [Related]
62. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Spinelli MA; Haberer JE; Chai PR; Castillo-Mancilla J; Anderson PL; Gandhi M
Curr HIV/AIDS Rep; 2020 Aug; 17(4):301-314. PubMed ID: 32424549
[TBL] [Abstract][Full Text] [Related]
63. Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.
Gandhi M; Gandhi RT; Stefanescu A; Bosch RJ; Cyktor JC; Horng H; Louie A; Phung N; Eron JJ; Hogg E; Macatangay BJC; Hensel C; Fletcher CV; Mellors JW; McMahon DK;
J Infect Dis; 2018 Jun; 218(2):234-238. PubMed ID: 29529230
[TBL] [Abstract][Full Text] [Related]
64. Early post-partum viremia predicts long-term non-suppression of viral load in HIV-positive women on ART in Malawi: Implications for the elimination of infant transmission.
Landes M; van Lettow M; van Oosterhout JJ; Schouten E; Auld A; Kalua T; Jahn A; Tippett Barr BA
PLoS One; 2021; 16(3):e0248559. PubMed ID: 33711066
[TBL] [Abstract][Full Text] [Related]
65. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
Castillo-Mancilla JR; Searls K; Caraway P; Zheng JH; Gardner EM; Predhomme J; Bushman LR; Anderson PL; Meditz AL
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):428-32. PubMed ID: 25328112
[TBL] [Abstract][Full Text] [Related]
66. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.
El-Khatib Z; Ekstrom AM; Coovadia A; Abrams EJ; Petzold M; Katzenstein D; Morris L; Kuhn L
BMC Public Health; 2011 Feb; 11():88. PubMed ID: 21303548
[TBL] [Abstract][Full Text] [Related]
67. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
[TBL] [Abstract][Full Text] [Related]
68. Comparison of guidelines for HIV viral load monitoring among pregnant and breastfeeding women in sub-Saharan Africa.
Lesosky M; Raboud JM; Glass T; Brummel SS; Ciaranello AL; Currier JS; Essajee S; Havlir DV; Koss CA; Ogwu A; Shapiro RL; Abrams EJ; Myer L
AIDS; 2020 Feb; 34(2):311-315. PubMed ID: 31634186
[TBL] [Abstract][Full Text] [Related]
69. Sexual violence and antiretroviral adherence among women of reproductive age in African population-based surveys: the moderating role of the perinatal phase.
Schrubbe LA; Stöckl H; Hatcher AM; Calvert C
J Int AIDS Soc; 2023 Jun; 26(6):e26129. PubMed ID: 37306126
[TBL] [Abstract][Full Text] [Related]
70. Drug concentrations in hair and dried blood spots as PrEP adherence metrics during pregnancy and postpartum.
Wu L; Kinuthia J; Anderson PL; Baeten JM; Dettinger JC; Gandhi M; Gomez L; John-Stewart G; Marwa MM; Ngumbau N; Otieno F; Omondi P; Odhiambo B; Watoyi S; Pintye J
J Infect Dis; 2024 May; ():. PubMed ID: 38700101
[TBL] [Abstract][Full Text] [Related]
71. Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment.
Chohan BH; Ronen K; Khasimwa B; Matemo D; Osborn L; Unger JA; Drake AL; Beck IA; Frenkel LM; Kinuthia J; John-Stewart G
PLoS One; 2021; 16(8):e0256249. PubMed ID: 34407133
[TBL] [Abstract][Full Text] [Related]
72. Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.
Gandhi M; Bacchetti P; Spinelli MA; Okochi H; Baeten JM; Siriprakaisil O; Klinbuayaem V; Rodrigues WC; Wang G; Vincent M; Cressey TR; Drain PK
J Acquir Immune Defic Syndr; 2019 May; 81(1):72-77. PubMed ID: 30664078
[TBL] [Abstract][Full Text] [Related]
73. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
[TBL] [Abstract][Full Text] [Related]
74. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study.
Cook RL; Zhou Z; Kelso-Chichetto NE; Janelle J; Morano JP; Somboonwit C; Carter W; Ibanez GE; Ennis N; Cook CL; Cohen RA; Brumback B; Bryant K
Addict Sci Clin Pract; 2017 Sep; 12(1):22. PubMed ID: 28950912
[TBL] [Abstract][Full Text] [Related]
75. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
van Zyl G; Jennings L; Kellermann T; Nkantsu Z; Cogill D; van Schalkwyk M; Spinelli M; Decloedt E; Orrell C; Gandhi M
AIDS; 2022 Nov; 36(14):2057-2062. PubMed ID: 36305182
[TBL] [Abstract][Full Text] [Related]
76. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin.
Mboup A; Béhanzin L; Guédou F; Giguère K; Geraldo N; Zannou DM; Kêkê RK; Bachabi M; Gangbo F; Affolabi D; Marzinke MA; Hendrix C; Diabaté S; Alary M
Medicine (Baltimore); 2020 May; 99(21):e20063. PubMed ID: 32481273
[TBL] [Abstract][Full Text] [Related]
77. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
78. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
[TBL] [Abstract][Full Text] [Related]
79. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
Coyle RP; Schneck CD; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL; Castillo-Mancilla JR
AIDS Behav; 2019 Dec; 23(12):3493-3502. PubMed ID: 30798457
[TBL] [Abstract][Full Text] [Related]
80. Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
Marryshow TA; Muhairwe J; Tang A; Molulela MMM; Matta R; Jordan MR
Int J STD AIDS; 2022 Jul; 33(8):777-783. PubMed ID: 35611960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
